2021
AGA Clinical Practice Guidelines on Intragastric Balloons in the Management of Obesity
Muniraj T, Day LW, Teigen LM, Ho EY, Sultan S, Davitkov P, Shah R, Murad MH. AGA Clinical Practice Guidelines on Intragastric Balloons in the Management of Obesity. Gastroenterology 2021, 160: 1799-1808. PMID: 33832655, DOI: 10.1053/j.gastro.2021.03.003.Peer-Reviewed Original Research
2020
Technical Review on the Management of Eosinophilic Esophagitis: A Report From the AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters
Rank M, Sharaf R, Furuta G, Aceves S, Greenhawt M, Spergel J, Falck-Ytter Y, Dellon E, Institute A, Chachu K, Day L, Lebwohl B, Muniraj T, Patel A, Peery A, Shah R, Singh H, Singh S, Spechler S, Sultan S, Su G, Thrift A, Weiss J, Weizman A, collaborators J, Bernstein J, Dinakar C, Golden D, Khan D, Lieberman J, Oppenheimer J, Shaker M, Stukus D, Wallace D, Wang J. Technical Review on the Management of Eosinophilic Esophagitis: A Report From the AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters. Gastroenterology 2020, 158: 1789-1810.e15. PMID: 32359563, PMCID: PMC9473155, DOI: 10.1053/j.gastro.2020.02.039.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, TopicalAdultAdvisory CommitteesAge FactorsAllergy and ImmunologyChildDilatationEosinophilic EsophagitisEosinophilsEsophagoscopyEvidence-Based MedicineFood HypersensitivityFood, FormulatedGastroenterologyGlucocorticoidsHumansProton Pump InhibitorsSocieties, MedicalTreatment OutcomeUnited StatesConceptsShort-term treatment periodEsophageal eosinophil countsHigh-power fieldLow certaintyTopical glucocorticosteroidsModerate certaintyEosinophilic esophagitisEosinophil countTreatment periodPractice parametersAmerican Gastroenterological Association InstituteAnti-IgE therapyAnti-TNF therapyChronic inflammatory conditionsProton pump inhibitorsJoint Task ForceDiet eliminationDietary eliminationElimination dietEoE managementEsophageal eosinophiliaMaintenance therapyRecommendations AssessmentElemental dietEsophageal dilationAGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis
Feuerstein J, Isaacs K, Schneider Y, Siddique S, Falck-Ytter Y, Singh S, Chachu K, Day L, Lebwohl B, Muniraj T, Patel A, Peery A, Shah R, Sultan S, Singh H, Singh S, Spechler S, Su G, Thrift A, Weiss J, Weizman A, Feuerstein J, Singh S, Isaacs K, Schneider Y, Falck-Ytter Y, Siddique S, Allegretti J, Terdiman J, Singh S, Siddique S. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology 2020, 158: 1450-1461. PMID: 31945371, PMCID: PMC7175923, DOI: 10.1053/j.gastro.2020.01.006.Peer-Reviewed Original ResearchAdultBiological ProductsClinical Decision-MakingClinical Trials as TopicColectomyColitis, UlcerativeColonColonoscopyDrug Therapy, CombinationEvidence-Based MedicineGastroenterologyGlucocorticoidsHumansImmunologic FactorsIntestinal MucosaSeverity of Illness IndexSocieties, MedicalTreatment OutcomeUnited States
2012
Diabetes and pancreatic cancer.
Muniraj T, Chari ST. Diabetes and pancreatic cancer. Minerva Gastroenterology 2012, 58: 331-45. PMID: 23207610, PMCID: PMC3932318.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsBody Mass IndexClinical Trials as TopicDiabetes Mellitus, Type 2Early Detection of CancerEvidence-Based MedicineGlobal HealthGlucose IntoleranceHumansHyperinsulinismHypoglycemic AgentsInsulin GlargineInsulin, Long-ActingMeta-Analysis as TopicMetforminObesityPancreatic NeoplasmsPrevalenceRisk AssessmentRisk FactorsConceptsType 2 diabetesNew-onset diabetesPancreatic cancerPancreatic cancer-associated diabetesAnti-diabetic medicationsDuration of diseasePancreatic cancer patientsYears of ageGlucose toleranceCancer patientsOnset diabetesHigh riskEpidemiological studiesDiabetesCancerAdditional markersModest increaseRiskInverse relationshipRecent studiesMedicationsPatientsDisease